Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Papillomavirus Infections 1Carcinoma in Situ 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 16Papillomavirus Vaccines 12Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 8Vaccines 5Human Papillomavirus DNA Tests 5Colposcopy 5Specimen Handling 4Blood Specimen Collection 4Watchful Waiting 3Vaginal Smears 3Patient Navigation 3Engerix-B 3Educational Status 3fludarabine phosphate 2fludarabine 2artesunic acid 2artemisinin 2aldesleukin 2Vaccines, Synthetic 2Standard of Care 2Practice Guidelines as Topic 2Polymerase Chain Reaction 2Mass Screening 2Light Coagulation 2Imiquimod 2Human Papillomavirus Recombinant Vaccine nonavalent 2GX-188 vaccine 2Early Intervention, Educational 2Data Collection 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Papillomavirus Infections × Meperidine × Gynecologic × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡